Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05219994

Enrollment

Registered

2022-02-02

Start date

2020-09-09

Completion date

2023-05-10

Last updated

2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Interventions

OTHERHyperoxia Exposure

2 hours of hyperoxia exposure during OGTT

OTHERNormoxia Exposure

2 hours of normoxia exposure during OGTT

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

After screening, participants will complete two study visits.

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy, * type 2 diabetes * BMI 18-40 kg/m2, * non-pregnant, * non-breastfeeding, * non-nicotine users.

Exclusion criteria

* cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke; * renal or hepatic diseases; * active cancer; * autoimmune diseases; * immunosuppressant therapy; * excessive alcohol consumption (\>14 drinks/week); * current nicotine use; * foot ulcers; * diabetic neuropathy; * medication directly influencing sympathetic nervous system activity

Design outcomes

Primary

Measure	Time frame
Glucose change in response to OGTT	2 hours post glucose ingestion
Insulin change in response to OGTT	2 hours post glucose ingestion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026